Capsule Summary Slidesets

Share

Program Content

Activities

  • Novel Anti-CD33 ADC in R/R AML
    Phase I Study of IMGN779, a Novel CD33-Targeted ADC, in Relapsed/Refractory CD33+ Acute Myeloid Leukemia
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 03, 2018

    Expires: December 02, 2019

  • Sequential HCVAD, Blinatumomab in Ph- B-Cell ALL
    Phase II Trial of Sequential HCVAD With Blinatumomab as Frontline Therapy for Adults With Ph-Negative B-Cell ALL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 04, 2018

    Expires: December 03, 2019

  • Blinatumomab in Older ALL
    Phase II SWOG 1318: First-line Blinatumomab Followed by POMP Maintenance in Older Patients Newly Diagnosed With Ph-Negative B-Cell ALL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 03, 2018

    Expires: December 02, 2019

  • Generic vs Branded Imatinib in CML
    Generic vs Brand Name Imatinib for Untreated Chronic-Phase Chronic Myeloid Leukemia: Findings From an Observational Cohort Study
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 05, 2018

    Expires: December 04, 2019

  • Venetoclax + HMA in AML
    Phase Ib Trial: Frontline Venetoclax + Decitabine or Azacitidine in Older Patients With Untreated AML Who Are Ineligible for Intensive Chemotherapy
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 05, 2018

    Expires: December 04, 2019

  • BLAST: Blinatumomab
    Long-term OS Follow-up of Phase II BLAST: Blinatumomab in Adults With Ph-Negative B-Cell Precursor ALL Who Are MRD Positive
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 07, 2018

    Expires: December 06, 2019

  • <i>IDH1/2</i> Inhibition + Chemo
    Ivosidenib or Enasidenib Plus Standard Induction and Consolidation Chemotherapy in Newly Diagnosed, IDH1/IDH2-Mutated AML
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 18, 2018

    Expires: December 17, 2019

  • QuANTUM-R Final Analysis
    QuANTUM-R: Phase III Trial of Quizartinib in Patients With FLT3-ITD–Mutated Relapsed/Refractory AML
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 17, 2018

    Expires: December 16, 2019

  • Gilteritinib in ND AML
    Phase I Study of Gilteritinib Combined With 7+3 Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia: Updated Results
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 05, 2018

    Expires: December 04, 2019

  • SORMAIN: Sorafenib in AML
    SORMAIN: Sorafenib vs Placebo Maintenance Therapy After Allogeneic SCT in FLT3-ITD AML
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 10, 2018

    Expires: December 09, 2019

  • IO/Mini-HCVD ± Blina in ALL
    Phase II Study: Inotuzumab Ozogamicin + Low-Intensity Chemo ± Blinatumomab in Newly Diagnosed Older Patients With Ph- ALL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

Provided by

ProCE Banner

Supporters

AbbVie

AstraZeneca

Celgene

Dova Pharmaceuticals

Gilead Text

Incyte

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals, Inc.

Novartis Pharmaceuticals Corporation

Seagen

Takeda Oncology